DNAR-10. PHASE I CLINICAL TRIAL OF PEPOSERTIB PLUS RADIOTHERAPY IN ADULTS WITH NEWLY-DIAGNOSED MGMT-UNMETHYLATED GLIOBLASTOMA
Sign Up to like & getrecommendations! Published in 2024 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noae165.0461
Abstract: DNA-dependent protein kinase (DNA-PK) is an attractive target in GBM because it promotes unwanted DNA repair and renders cancer cells less vulnerable to DNA damaging agents, such as radiotherapy (RT). Peposertib, a small molecule inhibitor… read more here.
Keywords: newly diagnosed; peposertib plus; mgmt unmethylated; cell ... See more keywords
NCOG-64. Combined adjunctive Perampanel and Memantine with standard of care chemoradiotherapy in newly diagnosed glioblastoma patients led to longer adjuvant treatment and prolonged functional independence: a single institution case series
Sign Up to like & getrecommendations! Published in 2025 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noaf201.1331
Abstract: Standard glioblastoma treatment benefits MGMT methylated patients more than unmethylated ones, often leading to abbreviated adjuvant therapy in MGMT unmethylated patients. Historically, 47% of glioblastoma patients completed six cycles of adjuvant temozolomide. A recent study… read more here.
Keywords: glioblastoma patients; mgmt unmethylated; treatment; functional independence ... See more keywords
ACTR-06. CLINICAL TRIAL OF VAL-083 IN NEWLY DIAGNOSED MGMT-UNMETHYLATED GBM: HALF-WAY REPORT
Sign Up to like & getrecommendations! Published in 2019 at "Neuro-Oncology"
DOI: 10.1093/neuonc/noz175.050
Abstract: Approximately 60% of glioblastoma multiforme (GBM) patients possess an unmethylated methylguanine DNA-methyltransferase (MGMT gene, which confers a limited response to standard of care treatment with temozolomide (TMZ) resulting in a lower survival. VAL-083 is a… read more here.
Keywords: newly diagnosed; val; mgmt unmethylated; val 083 ... See more keywords
Abstract CT272: Phase 2 study of dianhydrogalactitol (VAL-083) in patients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent or adjuvant setting
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct272
Abstract: Glioblastoma (GBM) is the most common and aggressive primary brain cancer. Current standard-of-care for glioblastoma (GBM) includes surgery followed by concurrent therapy with radiation and temozolomide (TMZ) followed by adjuvant TMZ (days 1-5 every 28… read more here.
Keywords: glioblastoma; gbm; mgmt unmethylated; group ... See more keywords
Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.tps2095
Abstract: TPS2095 Background: Glioblastoma (GBM) is characterized by a low mutational burden limiting the number of neoantigen targets for cancer vaccines. Vaccination against tumor-associated antigens over-presented via MHC class I and II in GBM is an… read more here.
Keywords: newly diagnosed; glioblastoma; part; mgmt unmethylated ... See more keywords